IPH5201 as monotherapy or in combination with durvalumab +/- oleclumab in participants with advanced solid tumors.

Study identifier:D6770C00001

ClinicalTrials.gov identifier:NCT04261075

EudraCT identifier:2019-004579-38

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination with Durvalumab ± Oleclumab in Advanced Solid Tumors

Medical condition

Advanced Solid Tumors

Phase

Phase 1

Healthy volunteers

No

Study drug

IPH5201, Durvalumab

Sex

All

Actual Enrollment

57

Study type

Interventional

Age

18 Years - 101 Years

Date

Study Start Date: 03 Mar 2020
Primary Completion Date: 16 Jun 2022
Study Completion Date: 16 Jun 2022

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria